Multicenter, randomized, double-blind, placebo-controlled, parallel group study to assess the
efficacy and safety of metformin treatment at a dose of 1700 mg / day in adults with
Huntington's disease.
The study consists of a screening period (2 to 4 weeks), followed by a 52-week double-blind
treatment period and a follow-up visit (one month after the end of treatment).